Sichenzia Ross Ference LLP Represents AIT Therapeutics in $8 Million Private Placement
Press Release – New York, NY – June 4, 2019 – Sichenzia Ross Ference LLP announced today that it has represented AIT Therapeutics, Inc. (NASDAQ:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, in a $8 million private placement of its common stock.
The Company issued approximately 1.6 million shares of common stock at a purchase price of $5.00 per share. The private placement was made directly by the Company without an underwriter or placement agent.
The Sichenzia Ross Ference team was led by Partners Gregory Sichenzia and Avital Perlman.
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020
- Coronavirus (Covid 19) Update - March 16, 2020
- Founding Partner Gregory Sichenzia Featured in Law360 Article on Coronavirus-fueled Market Volatility - March 10, 2020